Morand EF - Search Results

1

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.

Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R. Morand EF, et al. Ann Rheum Dis. 2018 May;77(5):706-713. doi: 10.1136/annrheumdis-2017-212504. Epub 2018 Feb 2. Ann Rheum Dis. 2018. PMID: 29420200 Free PMC article. Clinical Trial.

2

Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis.

Morand EF, McCloud PI, Littlejohn GO. Morand EF, et al. Ann Rheum Dis. 1992 Dec;51(12):1318-21. doi: 10.1136/ard.51.12.1318. Ann Rheum Dis. 1992. PMID: 1485814 Free PMC article.

3

Fibromyalgia syndrome and disease activity in systemic lupus erythematosus.

Morand EF, Miller MH, Whittingham S, Littlejohn GO. Morand EF, et al. Lupus. 1994 Jun;3(3):187-91. doi: 10.1177/096120339400300310. Lupus. 1994. PMID: 7951304

4

Single anticardiolipin measurement in the routine management of patients with systemic lupus erythematosus.

Axtens RS, Miller MH, Littlejohn GO, Topliss DJ, Morand EF. Axtens RS, et al. Among authors: morand ef. J Rheumatol. 1994 Jan;21(1):91-3. J Rheumatol. 1994. PMID: 8151597

5

Methotrexate use in systemic lupus erythematosus.

Kipen Y, Littlejohn GO, Morand EF. Kipen Y, et al. Among authors: morand ef. Lupus. 1997;6(4):385-9. doi: 10.1177/096120339700600407. Lupus. 1997. PMID: 9175024 Clinical Trial.

6

Body composition in systemic lupus erythematosus.

Kipen Y, Strauss BJ, Morand EF. Kipen Y, et al. Among authors: morand ef. Br J Rheumatol. 1998 May;37(5):514-9. doi: 10.1093/rheumatology/37.5.514. Br J Rheumatol. 1998. PMID: 9651078

7

Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus.

Kipen Y, Briganti E, Strauss B, Will R, Littlejohn G, Morand E. Kipen Y, et al. J Rheumatol. 1999 Feb;26(2):310-7. J Rheumatol. 1999. PMID: 9972964

8

Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus.

Kipen Y, Briganti EM, Strauss BJ, Littlejohn GO, Morand EF. Kipen Y, et al. Among authors: morand ef. Rheumatology (Oxford). 1999 Jan;38(1):59-65. doi: 10.1093/rheumatology/38.1.59. Rheumatology (Oxford). 1999. PMID: 10334684

9

Macrophage migration inhibitory factor in systemic lupus erythematosus.

Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Foote A, et al. Among authors: morand ef. J Rheumatol. 2004 Feb;31(2):268-73. J Rheumatol. 2004. PMID: 14760795

10

Smooth muscle myopathy as an underrecognized manifestation of active systemic lupus erythematosus.

Ngian GS, Naidoo P, Morand EF, Hoi AY. Ngian GS, et al. Among authors: morand ef. Intern Med J. 2011 Jun;41(6):495-8. doi: 10.1111/j.1445-5994.2011.02505.x. Intern Med J. 2011. PMID: 21707895

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

339 results

Search Page

Filters